Stephen D Silberstein
Overview
Explore the profile of Stephen D Silberstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
249
Citations
6042
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pozo-Rosich P, Alpuente A, Silberstein S, Burstein R
Nat Rev Neurol
. 2024 Aug;
20(9):555-568.
PMID: 39160284
OnabotulinumtoxinA (BTX-A) was first linked to beneficial effects in migraine 25 years ago and was approved by the FDA for preventive treatment of chronic migraine in 2010. The treatment has...
2.
Silberstein S, Diener H, Dodick D, Sommer K, Lipton R
Headache
. 2024 Jul;
64(7):838-848.
PMID: 38982666
Objective: To characterize the long-term (56-week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to <15 headache days/month with treatment. Background: There are...
3.
Vives-Mestres M, Casanova A, Silberstein S, Hershey A, Orr S
Headache
. 2024 Jun;
64(8):995-1004.
PMID: 38932610
Objective: To describe the association between day-to-day peak pain severity and clinical factors in individuals with chronic migraine (CM). Background: Little is known about how clinical factors relate to day-to-day...
4.
Yuan H, Silberstein S
Med
. 2024 Mar;
5(3):179-180.
PMID: 38460496
Treating migraine attacks early at the onset of a headache is a common proven strategy. But does this strategy work before headache onset? In the PRODROME trial, Dodick et al....
5.
Duncan C, Silberstein S
Handb Clin Neurol
. 2024 Feb;
199:219-241.
PMID: 38307648
The evidence base for migraine prevention in both episodic and chronic migraine is outlined. The older oral preventatives, including antidepressants, antihypertensives, serotonin antagonists, antiepileptics, and calcium channel antagonists, and newer...
6.
Fishman M, Chitneni A, Abd-Elsayed A, Grodofsky S, Scherer A, Schetzner B, et al.
Brain Sci
. 2023 Dec;
13(12).
PMID: 38137166
Headache is a leading cause of disability and suffering. One major challenge in developing device treatments is demonstrating their efficacy given devices' often-high placebo rate. This paper reviews the importance...
7.
Turkel C, Aurora S, Diener H, Dodick D, Lipton R, Silberstein S, et al.
Medicine (Baltimore)
. 2023 Jul;
102(S1):e32600.
PMID: 37499085
Chronic migraine (CM) is a neurological disease characterized by frequent migraine attacks that prevent affected individuals from performing daily activities of living, significantly diminish quality of life, and increase familial...
8.
Tepper S, Lipton R, Silberstein S, Kudrow D, Ashina M, Reuter U, et al.
Headache
. 2023 Jun;
63(6):730-742.
PMID: 37313616
Objective: Assess the long-term efficacy and safety of erenumab in patients with chronic migraine with acute medication overuse. Background: Overuse of acute medication in patients with chronic migraine has been...
9.
Ceriani C, Silberstein S
Expert Opin Pharmacother
. 2023 Mar;
24(5):617-627.
PMID: 36946205
Introduction: In this article, we discuss menstrual migraine (MM), which can be categorized as menstrually related migraine (MRM) or pure menstrual migraine (PMM). MM attacks are often longer, more severe,...
10.
Silberstein S, Reshef S, Cohen J, Gandhi S, Seminerio M, Ramirez Campos V, et al.
Adv Ther
. 2022 Nov;
40(2):445-459.
PMID: 36350532
Introduction: Through 2018, three calcitonin gene-related peptide pathway-targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab. Methods: This...